These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Valproate-induced lethal hyperammonaemic coma in a carrier of ornithine carbamoyltransferase deficiency. Tokatli A; Coşkun T; Cataltepe S; Ozalp I J Inherit Metab Dis; 1991; 14(5):836-7. PubMed ID: 1779634 [No Abstract] [Full Text] [Related]
23. Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman. Mallet L; Babin S; Morais JA Ann Pharmacother; 2004 Oct; 38(10):1643-7. PubMed ID: 15316109 [TBL] [Abstract][Full Text] [Related]
24. Heterozygote ornithine transcarbamylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate therapy. Honeycutt D; Callahan K; Rutledge L; Evans B Neurology; 1992 Mar; 42(3 Pt 1):666-8. PubMed ID: 1549234 [TBL] [Abstract][Full Text] [Related]
25. Serum carnitine, beta-hydroxybutyrate and ammonia levels during valproic acid therapy. Toksoy HB; Tanzer FN; Atalay A Turk J Pediatr; 1995; 37(1):25-9. PubMed ID: 7732605 [TBL] [Abstract][Full Text] [Related]
26. Valproate as a cause of hyperammonemia in heterozygotes with ornithine-transcarbamylase deficiency. Leão M Neurology; 1995 Mar; 45(3 Pt 1):593-4. PubMed ID: 7898728 [No Abstract] [Full Text] [Related]
27. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status. Hamed SA; Abdella MM Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440 [TBL] [Abstract][Full Text] [Related]